A comprehensive analysis of the prognostic and immunological role of ANK3 in pan-cancer

被引:3
作者
Tan, Yunfei [1 ]
Meng, Wei [1 ]
Jiang, Zhaosheng [2 ]
Li, Ningning [3 ]
Zhang, Tong [3 ]
Zhang, Jiayi [3 ]
Ma, Limin [1 ]
Guan, Yangbo [1 ,4 ,5 ]
机构
[1] Nantong Univ, Affiliated Hosp, Med Sch, Dept Urol, 20 Xisi Rd, Nantong 226001, Peoples R China
[2] Nantong Hosp Tradit Chinese Med, Dept Urol, Nantong, Peoples R China
[3] Nantong Univ, Xinglin Coll, Nantong, Peoples R China
[4] Nantong Univ, Affiliated Hosp, Dept Clin Biobank, Nantong, Peoples R China
[5] Nantong Univ, Affiliated Hosp, Inst Oncol, Nantong, Peoples R China
关键词
Ankyrin-3 ( ANK3 ); pan; -cancer; prognosis; immune; bioinformatics; GENE-EXPRESSION; ANKYRIN-REPEAT; IMMUNE; MUTATION; CELLS;
D O I
10.21037/tcr-23-2379
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Cancer is a common cause of death around the world. Immunotherapy plays a significant role in cancer treatment but still has limitations. The ankyrin-3 ( ANK3 ) gene has been shown to have a variety of biological roles and has also been shown to be closely linked to individual cancers. Methods: We systematically investigated the role of ANK3 in pan -cancer, particularly in relation to immunity. We collected data from a number of databases, including the The University of ALabama at Birmingham CANcer data analysis Portal (UALCAN), tumor -immune system interactions (TISIDB), cBioPortal, Tumor Immune Estimation Resource (TIMER), Search Tool for the Retrieval of Interacting Genes/Proteins (STRING), BioGRID, and SangerBox databases. R (version 3.6.3) was used for the statistical analysis and data visualization. The expression of ANK3 in tumors and its effects on patient prognosis, immune infiltration, neoantigens, the microenvironment, immune checkpoints (ICs), the tumor mutation burden, microsatellite instability (MSI), methylation, mismatch repair (MMR) genes, and cancer -associated fibroblasts were investigated. A gene set enrichment analysis (GSEA) was also conducted. Results: The ANK3 gene was differentially expressed at the messenger RNA (mRNA) and protein levels in various human tumors. The prognosis of patients with different types of malignancies was correlated with the level of ANK3 expression. The immunological microenvironment was also linked to ANK3 expression, especially in colon adenocarcinoma (COAD), kidney renal clear cell carcinoma (KIRC), and liver hepatocellular carcinoma (LIHC). ANK3 was also associated with ICs, immune neoantigens, MSI, the tumor mutation load, MMR genes, and DNA methylation. Finally, we found the key pathway related to the ANK3 gene through the enrichment analysis. Conclusions: ANK3 could serve as a new biomarker specific to prognosis and immunotherapy in various cancers. Our findings could contribute to the development of novel strategies for treating malignancies.
引用
收藏
页码:1091 / 1113
页数:25
相关论文
共 37 条
[1]   Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation [J].
Anderson, Ana C. ;
Joller, Nicole ;
Kuchroo, Vijay K. .
IMMUNITY, 2016, 44 (05) :989-1004
[2]   Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups [J].
Andrews, Lawrence P. ;
Yano, Hiroshi ;
Vignali, Dario A. A. .
NATURE IMMUNOLOGY, 2019, 20 (11) :1425-1434
[3]   MNF, an ankyrin repeat protein of myxoma virus, is part of a native cellular SCF complex during viral infection [J].
Blanie, Sophie ;
Gelfi, Jacqueline ;
Bertagnoli, Stephane ;
Camus-Bouclainville, Christelle .
VIROLOGY JOURNAL, 2010, 7
[4]   The ever-increasing importance of cancer as a leading cause of premature death worldwide [J].
Bray, Freddie ;
Laversanne, Mathieu ;
Weiderpass, Elisabete ;
Soerjomataram, Isabelle .
CANCER, 2021, 127 (16) :3029-3030
[5]   Upregulation of FBXW7 Suppresses Renal Cancer Metastasis and Epithelial Mesenchymal Transition [J].
Cai, Yangke ;
Zhang, Meng ;
Qiu, Xiaofu ;
Wang, Bingwei ;
Fu, Yu ;
Zeng, Jun ;
Bai, Jian ;
Yang, Guosheng .
DISEASE MARKERS, 2017, 2017
[6]   UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses [J].
Chandrashekar, Darshan S. ;
Bashel, Bhuwan ;
Balasubramanya, Sai Akshaya Hodigere ;
Creighton, Chad J. ;
Ponce-Rodriguez, Israel ;
Chakravarthi, Balabhadrapatruni V. S. K. ;
Varambally, Sooryanarayana .
NEOPLASIA, 2017, 19 (08) :649-658
[7]   Turning foes to friends: targeting cancer-associated fibroblasts [J].
Chen, Xueman ;
Song, Erwei .
NATURE REVIEWS DRUG DISCOVERY, 2019, 18 (02) :99-115
[8]   Targeting Programmed Cell Death-1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapy [J].
Constantinidou, Anastasia ;
Alifieris, Constantinos ;
Trafalis, Dimitrios T. .
PHARMACOLOGY & THERAPEUTICS, 2019, 194 :84-106
[9]  
Cui YA, 2022, AM J CANCER RES, V12, P1766
[10]   Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer [J].
de Rodas, Miguel Lopez ;
Nagineni, Venkata ;
Ravi, Arvind ;
Datar, Ila J. ;
Mino-Kenudson, Mari ;
Corredor, German ;
Barrera, Cristian ;
Behlman, Lindsey ;
Rimm, David L. ;
Herbst, Roy S. ;
Madabhushi, Anant ;
Riess, Jonathan W. ;
Velcheti, Vamsidhar ;
Hellmann, Matthew D. ;
Gainor, Justin ;
Schalper, Kurt A. .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (06)